Harmony Biosciences Stock (NASDAQ:HRMY)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$28.79

52W Range

$25.52 - $40.87

50D Avg

$34.54

200D Avg

$33.82

Market Cap

$1.61B

Avg Vol (3M)

$867.10K

Beta

0.91

Div Yield

-

HRMY Company Profile


Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

268

IPO Date

Aug 19, 2020

Website

HRMY Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22
United States$500.00M$500.00M

Fiscal year ends in Dec 25 | Currency in USD

HRMY Financial Summary


Dec 25Dec 24Dec 23
Revenue$868.45M$714.73M$582.02M
Operating Income$208.47M$190.83M$192.03M
Net Income$158.69M$145.49M$128.85M
EBITDA$208.47M$233.41M$221.51M
Basic EPS$2.76$2.56$2.17
Diluted EPS$2.71$2.51$2.13

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts


Q4 25Feb 24, 26 | 8:30 AM
Q3 25Nov 04, 25 | 8:30 AM
Q2 25Aug 05, 25 | 8:30 AM

Peer Comparison


TickerCompany
SIONSionna Therapeutics, Inc.
NUVBNuvation Bio Inc.
ABCLAbCellera Biologics Inc.
BHVNBiohaven Ltd.
IMCRImmunocore Holdings plc
CLDXCelldex Therapeutics, Inc.
VERAVera Therapeutics, Inc.
AUPHAurinia Pharmaceuticals Inc.
MNKDMannKind Corporation
JANXJanux Therapeutics, Inc.